Navigation Links
Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
Date:10/11/2010

l therapeutic benefit may be achieved with DCCR, helping them reach lipid goals."

Patients taking DCCR experience mostly mild to moderate, transient adverse events, the most frequent of which included increases in fasting plasma glucose that are similar to or less than those seen with niacin, another lipid-lowering drug, peripheral edema similar to what is seen with calcium channel blocking antihypertensives, and headaches.

About Very High Triglycerides

Hypertriglyceridemia, a disease where patients have high blood levels of triglycerides, is associated with increased risk of coronary heart disease even after LDL-cholesterol targets have been achieved. Very high triglycerides are associated with an increased risk of developing pancreatitis. There are approximately 4 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides, Lovaza® and fenofibrate, while effective, also cause significant elevations in LDL-cholesterol.

About Essentialis

Essentialis is a pharmaceutical company based in San Diego, CA focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases.


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Essentialis to Submit SPA for Hypertriglyceridemia
2. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
3. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
4. American Medical Systems Strengthens Global Expansion With GreenLight HPS® Acquisitions in Australia
5. PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
6. Webmedx Strengthens Quality Program and Improves Patient Safety in Compliance with New Industry Standards for Clinical Documentation
7. Pepscan Therapeutics Strengthens Management Team
8. Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo
9. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
10. Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering
11. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... ANGELES , Aug. 21, 2014 The spinal ... of the human body. Signals carried to and from the ... motor skills and nervous system. Injury or ailment here can ... or with a loss of control over their body. Though ... on a person,s life, there are more options available to ...
(Date:8/21/2014)... MISSISSAUGA, ON , Aug. 21, 2014 /CNW/ - Eisai ... in the introduction of the first-of-its-kind comic book available in ... educational tool, has been designed specifically to educate children and ... Canada affecting more than 300,000 Canadians. ... human health care (hhc) , in which the patient is ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... Endpoints Met; Data Demonstrate MoxDuo(TM) IR Provides Better ... BEDMINSTER, N.J., April 20 QRxPharma Limited (ASX: ... completion of a Phase 3 program pilot study ... IR against component doses of morphine and oxycodone. ...
... search for the cause of an inherited form of ... information about how the cancer develops and potentially sheds ... by researchers at Washington University School of ... in Washington, D.C., the International Pleuropulmonary Blastoma Registry at ...
Cached Medicine Technology:QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy 2QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy 3Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers 2Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers 3Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers 4Genetic Source of Rare Childhood Cancer Found; Gene is Implicated in Other Cancers 5
(Date:8/22/2014)... The ALS Association, along with its Western Pennsylvania ... Health Network as a Certified Treatment Center of ... (AGH), is the only ALS treatment program in western ... highest levels of established national standards of care in ... to as Lou Gehrig’s Disease. , Allegheny Health Network’ ...
(Date:8/22/2014)... This funding was made through an additional ... Therapeutics, Inc. in the form of a convertible promissory ... collaborate with Saneron on several fronts to enable the ... to regenerative therapies using cord blood to ... Chairman and Co-CEO of Cryo-Cell, stated. He continued, ...
(Date:8/22/2014)... Human induced pluripotent stem cells (hiPSCs) have ... they can be coaxed to turn into specific cells; ... They sometimes mutate, develop into tumors or produce other ... published in STEM CELLS Translational Medicine, researchers appear to ... the material used to reprogram the stem cell after ...
(Date:8/22/2014)... 22, 2014 The New Jersey ... Rutgers, the State University of New Jersey has joined ... media organization, to educate young people about health and ... the strengths of both organizations. , The partnership will ... communications fellowship program, and video communications. ChopChop Magazine ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3Health News:Removing Programming Material After Inducing Stem Cells Could Improve Their Regeneration Ability 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Reporter , MONDAY, March 26 (HealthDay News) -- Here,s a ... who eat chocolate regularly are somewhat skinnier than folks who ... that chowing down on chocolate will melt off your excess ... modest difference in body mass, or it might be a ...
... honored with the Distinguished Sonographer Award during the 2012 ... at the JW Marriott Desert Ridge Resort and Spa ... Sonographer Award is a means of recognizing and honoring ... to the growth and development of medical ultrasound. ...
... Lisa Esposito HealthDay Reporter , THURSDAY, March ... initiative since the Medicare and Medicaid programs of the ... presidency, is about to face its biggest challenge. ... unprecedented six hours of arguments over three days on ...
... , MONDAY, March 26 (HealthDay News) -- ... leading cause of death among women in the United ... clinics, a new study suggests. Researchers from ... that heart screenings performed during visits to obstetrician/gynecologists could ...
... cancer researcher Professor Jane Visavader has been selected to ... The fellowship recognises Professor Visvader,s research over the past ... that can give rise to all types of cells ... which different types of breast cancer arise., Professor Visvader, ...
... offering in late March a new stereotactic radiosurgery ... available. The new imaging and radiosurgery ... fast and precise noninvasive image-guided radiation therapy. Radiosurgery ... with high precision to a tumor. "Radiosurgery ...
Cached Medicine News:Health News:Does Chocolate Help You Stay Slim? 2Health News:Does Chocolate Help You Stay Slim? 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 2Health News:Supreme Court Prepares to Tackle Affordable Care Act 3Health News:Supreme Court Prepares to Tackle Affordable Care Act 4Health News:Supreme Court Prepares to Tackle Affordable Care Act 5Health News:Supreme Court Prepares to Tackle Affordable Care Act 6Health News:Ob/Gyn Visit a Good Time to Screen for Heart Disease: Study 2Health News:Professor Jane Visvader elected to Australian Academy of Science 2Health News:Cancer treatment system sculpts radiation beam to match shape of a tumor 2
... key challenges. Reducing costs while adjusting to ... Meeting ever-increasing expectations from more informed customers. ... with labor shortages. Providing value in managing ... theres targeted relief from a trusted partner ...
... The Roche Diagnostics Task Targeted ... state-of-the-art automation of pre- ... laboratories: decapping, sorting / archiving ... into bar code labeled secondary ...
... 20 years of experience in providing ... Life Sciences, the Freedom EVO platform ... for expansion according to future needs., ... Freedom EVOware, each system is equipped ...
... designed a flexible liquid handling system that ... three liquid handlers all on the same ... for targeted applications or custom-tailored to meet ... provide comprehensive systems that combine all the ...
Medicine Products: